Director/PDMR Share Purchases

RNS Number : 3642T
Cambridge Cognition Holdings PLC
22 July 2022
 

22 July 2022  

Cambridge Cognition Holdings Plc

("Cambridge Cognition", the "Company" or the "Group")

Director/PDMR Share Purchases

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, was informed on 21 July 2022 of the following purchases of the Company's ordinary shares by Directors and P DMRs of the Company .

The purchases made on 21 July 2022 are detailed in the table below:

Director/PDMR

No. of Ordinary Shares purchased

Purchase price per Ordinary Share

Total no. of Ordinary Shares held

Percentage ownership of total issued share capital

Matthew Stork

22,950

£1.13

147,950

0.47%

Stephen Symonds

22,950

£1.13

22,950

0.07%

 

Further information on the purchases is contained in the disclosure tables below.

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

For further information, please contact:

Cambridge Cognition Holdings Plc

Tel: 01223 810 700

Matthew Stork, Chief Executive Officer

press@camcog.com

Stephen Symonds, Chief Financial Officer




Panmure Gordon (UK) Ltd

(NOMAD and Joint Broker)

 

Tel: 020 78862500

Freddy Crossley / Emma Earl / Mark Rodgers

(Corporate Advisory)

Rupert Dearden

(Corporate Broking)



Dowgate Capital Limited (Joint Broker)

Tel: 020 3903 7715

David Poutney / James Serjeant




IFC Advisory Ltd (Financial PR and IR)

Tel: 020 3934 6630

Tim Metcalfe / Graham Herring / Zach Cohen

cog@investor-focus.co.uk

 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit  www.cambridgecognition.com

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Matthew Stork

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cambridge Cognition Holdings Plc

b)

LEI

213800SZKDIN122EPA96

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.01p each

 

 

GB00B8DV9647

b)

Nature of the transaction

Purchase of Shares

c)

Price(s) and volume(s)

   Price(s)

Volume(s)

£1.13

22,950

 

d)

Aggregated information

- Aggregated volume

- Price



22,950


£1.13

e)

Date of the transaction

21 July 2022

f)

Place of the transaction

London Stock Exchange

 

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Stephen Symonds

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cambridge Cognition Holdings Plc

b)

LEI

213800SZKDIN122EPA96

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.01p each

 

 

GB00B8DV9647

b)

Nature of the transaction

Purchase of Shares

c)

Price(s) and volume(s)

   Price(s)

Volume(s)

£1.13

22,950

 

d)

Aggregated information

- Aggregated volume

- Price



22,950


£1.13

e)

Date of the transaction

21 July 2022

f)

Place of the transaction

London Stock Exchange

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHPPURWMUPPGQG
UK 100

Latest directors dealings